About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics Holdings, Inc. (the "Company") is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and
commercializing prescription drugs, primarily for the U.S. market. Pernix Therapeutics, LLC is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding
into additional specialty segments. Pernix Therapeutics, LLC promotes branded products to physicians through its internal sales force. The Company's wholly-owned subsidiaries, Macoven
Pharmaceuticals, L.L.C., and Cypress Pharmaceuticals, Inc., market a portfolio of generic products.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "estimate,"
"plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "target" or
similar expressions are forward-looking statements. These statements reflect the Company's current views, expectations and beliefs concerning future events. In addition, any statements related
to Pernix's consideration of strategic alternatives and future strategy and plans with respect to its business
contained herein are forward-looking statements. Such plans, expectations and statements are as to future events and are not to be viewed as facts, and reflect various
assumptions of management of the Company and are subject to significant business, financial, economic, operating, competitive, litigation and other risks and uncertainties and contingencies
(many of which are difficult to predict and beyond the control of the Company) that could cause actual results to differ materially from the statements included herein. The inclusion of forward-looking
statements should not be regarded as a representation by Pernix that any of its plans will be achieved. Investors should note that many factors, including those
more fully described in Pernix's filings with the Securities and Exchange Commission ("SEC") (including,
but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2017 and its Quarterly Report on Form 10-Q for the Quarterly Period ended September 30, 2018 and subsequent
filings with the SEC), could affect the Company's future financial results and could cause actual results to differ materially from those expressed in forward-looking statements, such as those
contained in this press release. The forward-looking statements in this press release are qualified by risk factors identified by the Company. These risk factors, individually or in the aggregate,
could cause our actual results to differ materially from expected and historical results. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date hereof. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
LifeSci Advisors, LLC